Company intelligence / Profile preview

领泰生物医药

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Lead-Tech Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the discovery and development of innovative targeted protein degradation (TPD) medicines. The company leverages its proprietary Nano-PROTAC platform to create highly selective small molecule degraders for challenging targets in the fields of immunology and oncology. Its lead program, LT-002, is an orally bioavailable IRAK4 degrader currently in Phase 1 clinical trials for the treatment of inflammatory skin conditions like hidradenitis suppurativa. Lead-Tech is supported by prominent venture capital firms and aims to address significant unmet medical needs through its advanced protein degradation technology.

Therapeutic areas: OncologyDermatologyImmunology
Modalities: Proteolysis-targeting chimera therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on 领泰生物医药.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 领泰生物医药.

Explore the full profile